Back to top
more

Impax Laboratories, Inc. (IPXL)

(Real Time Quote from BATS)

$18.30 USD

18.30
3,041,017

0.00 (0.00%)

Updated May 4, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks News

Impax (IPXL) Up 35.3% Since Earnings Report: Can It Continue?

Impax (IPXL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL)

    Impax Laboratories (IPXL) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.

      New Strong Sell Stocks for March 6th

      Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

        Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates

        Impax Laboratories Inc. (IPXL) posted fourth-quarter 2016 adjusted earnings of 16 cents per share, in line with the Zacks Consensus Estimate.

          Impax Laboratories (IPXL) is Oversold: Can It Recover?

          Impax Laboratories, Inc. (IPXL) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

            Add These 5 Stocks with Low P/B Ratio to Your Portfolio

            P/B ratio = market capitalization/book value of equity

              7 Low Price-to-Cash-Flow Stocks for Assured Returns

              Investors always try to hit the jackpot while picking stocks. But striking the right chord each time is not easy unless you know the trick.

                Cymabay Therapeutics (CBAY) Rises: Stock Moves 9.2% Higher

                Cymabay Therapeutics, Inc. (CBAY) shares rose over 9% in the last trading session.

                  5 Value Stocks to Pick Using Price-to-Book Ratio

                  P/B ratio = market capitalization/book value of equity

                    Zacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and Cosan

                    Zacks.com featured highlights: General Motors, Citizens Financial Group, Impax Laboratories and Cosan

                      4 Low P/CF Stocks to Add More Value to Your Investment

                      Value style is considered one of the best practices when it comes to picking stocks.

                        5 Affordable Stocks with Impressive Returns

                        5 Affordable Stocks with Impressive Returns

                          Is Impax a Great Stock for Value Investors?

                          Value Investors might consider Impax Laboratories (IPXL) as a great pick on the back of its key value statistics.

                            Assembly Biosciences (ASMB) Looks Good: Stock Up 13.9%

                            Assembly Biosciences, Inc. (ASMB) was a big mover last session, as the company saw its shares rise nearly 14% on the day.

                              Ryan McQueeney headshot

                              Stock Market Roundup, Jan. 12: AMZN Jobs, FCAU Cheating, AKS & X Tank

                              As investors continued to worry about President-elect Trump's targeting of the pharma industry, new concerns about U.S. industrial stocks help drag the markets down in morning trading Thursday. Nevertheless, stocks bounced back thanks to overall bullish optimism, and the markets ended on a strong afternoon run that saw indexes down just marginally on the day.

                                Madeleine Johnson headshot

                                CVS Debuts Cheap EpiPen Alternative

                                On Thursday, leading drug store chain CVS Health Corp. (CVS) announced that it is now selling a cheaper alternative to Mylan's (MYL) EpiPen.

                                  Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

                                  Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

                                    Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

                                    Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

                                      Mylan (MYL) Launches Authorized Generic EpiPen at $300

                                      Mylan (MYL) announced the launch of the first generic version of its life-saving allergy treatment, EpiPen, at more than 50% discount to the branded product.

                                        Arpita Dutt headshot

                                        20 States Sue Teva, Mylan & Other Drug Companies for Price Fixing

                                        The lawsuit and the DoJ antitrust probe pose headline risk for generic companies like Mylan (MYL) and Teva (TEVA).

                                          Arpita Dutt headshot

                                          Generic Stocks Feel Pricing Heat, 1st Charges Filed in DoJ Antitrust Probe

                                          Key generic drugmakers including Teva (TEVA) saw their shares slip on news that the first charges have been filed in the investigation related to generic drug pricing.

                                            Ryan McQueeney headshot

                                            Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today

                                            Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.